One AI Stock to Buy for Life After Nvidia

One AI Stock to Buy for Life After Nvidia

Source: Shutterstock

Listen to the audio version of this article (generated by AI).

Tom Yeung here with your Sunday Digest.

In December 2000, with the Nasdaq-100 still in free fall, InvestorPlace’s global macro specialist, Eric Fry, recommended a funeral home operator that Wall Street considered a disaster by any measure.

A decade-long buying spree had saddled the company with $3.3 billion of debt. It had missed earnings and had recently fired 10 executive officers, including the son of its founder. By the end of 2000, The Wall Street Journal had named Service Corporation International (SCI) the worst one-year performer of its Shareholder Scoreboard, a list of America’s 1,000 largest firms.

Few people want to own a funeral home in the best of times. Even fewer did in 2000.

That was rather the point of Eric’s recommendation.

It turns out that SCI’s underlying business was stronger than its stock price. Death rates don’t follow the markets, and demand for funerals didn’t care if Cisco Systems Inc. (CSCO) was trading at $75 or $10. SCI became one of the greatest turnarounds in corporate history, rewarding Eric’s readers with a 2,900%-plus return.

That’s why it’s so important to pay attention when Eric is recommending shares of any “hated” company. And today, that brings us to a drug company in Hong Kong.

It’s one of three stocks in a new report Eric has prepared for his Life After Nvidia presentation, which premieres Monday at 10 a.m. Eastern. He’s agreed to let me share this one with you today. You can reserve a free seat for his event here.

The Drug Factory

Eric’s recommendation isn’t your typical drug developer. Rather than test thousands of physical compounds and see what works, it uses AI to invent drugs long before test tubes are touched.

It’s a fascinating process. Its AI system picks a disease target, designs thousands of molecules that might cure it, and then virtually trials each of these promising ideas to see which might work in the real world.

The company’s systems allow researchers to skip straight to the few candidates that deserve real-life tests. They also use AI to design and predict clinical trials, speeding up one of the other time-consuming parts of drug development.

Think of a master chef who can taste a recipe before cooking it. He can imagine every possible flavor combination and know precisely how ingredients will work together. That chef will be producing culinary inventions that no one has thought about before, simply because he’s saving enormous amounts of time by testing everything in his mind before a single real-world action is taken.

That’s how Insilico Medicine (ISLMF) has become such a breakout success. The firm has at least 30 drugs in its pipeline – the most among firms its size – and its therapies are aimed at treating everything from cancers to Parkinson’s disease. Its AI system is lightning-fast at identifying new drug candidates; on average, Insilico can get from target to drug candidate in 12 to 18 months, versus about the roughly four and a half years it takes everyone else. Unlike other drug developers, they don’t have to throw spaghetti at the wall to see what sticks.

I should also note that Insilico’s AI-designed drugs can do better than the ones discovered in the old-fashioned way. For instance, in 2020, Insilico began applying early versions of its AI to test therapies for idiopathic pulmonary fibrosis (IPF), a fatal lung-scarring disease that has flummoxed researchers for decades. By 2021, it had landed on a top candidate called Rentosertib to test in the real world.

Early trials have been a success. In a randomized trial published in Nature Medicine, patients on Rentosertib’s top dose regained lung capacity, the first drug to ever do that in patients with IPF. The drug is now in a 320-patient Phase III study, making it the first fully AI-designed medicine to get that far.

More recently, a separate Insilico drug for cancer shrank tumors in patients who had already failed up to six rounds of chemotherapy. Two of five patients at the top dose responded, and no one showed dose-limiting side effects. It’s still early days for this therapy, but it highlights how Insilico’s AI algorithms are creating drugs that humans alone could not.

The Industry Has Already Voted

Many of the top minds in healthcare have invested vast sums into Insilico to gain access to its AI drug factory.

As early as 2022, Sanofi SA (SNY) signed a deal with Insilico worth up to $1.2 billion to develop therapies for up to six new targets. Californian drug firm Exelixis Inc. (EXEL) inked an agreement the following year. Eli Lilly and Co. (LLY), Takeda Pharmaceutical Co. (TAK), and other major firms have since signed up.

In fact, 13 of the 20 largest pharmaceutical companies are now customers. Insilico has more than $10 billion in potential deal value if it hits all its milestones, (with $7.3 billion happening this year alone), and will likely see more partnerships as its AI process churns out more promising candidates.

The company has also become profitable thanks to these deals. In the first half of 2026, Insilico generated $35.5 million in net profits on $106 million in revenue. Analysts are modeling rapid growth ahead, with annual revenue hitting $284 million by 2028.

And No One Wants to Buy…

Yet, Insilico’s stock is down 56% from its February peak, including a 41% drop since early October.

So why is a profitable AI company with $10 billion of deals trading like a distressed funeral home operator? Several reasons.

  • Wrong exchange. Insilico primarily trades in Hong Kong, where AI stocks have plummeted on fears of a Chinese-related AI slowdown. AI stocks in mainland China stocks have now fallen 40% since July, dragging Hong Kong stocks down with them.
  • Insider selling. The venture funds that backed Insilico before its IPO are now cashing out. Warburg Pincus has sold nearly half its stake, and investors might be pre-empting December 30, when the one-year anniversary of Insilico’s listing frees up more.
  • Wrong sector. Insilico is a drug company. Much like funeral homes, pharmaceuticals make investors think about disease and death. Most would rather not.

None of these has anything to do with Insilico’s underlying business, which has been excellent. As mentioned earlier, the company flipped to positive profits in the first half of 2026, and it’s continued to forge ahead with discovering new therapies. Meanwhile, Insilico carries $584 million of cash and near-zero debt. That means every $1 invested in Insilico comes with 23 cents of cash on the company’s balance sheet.

It’s perhaps no surprise that the company’s two founders voluntarily added another six months to their lockup period last June. That means they cannot sell any stock until at least mid-2027.

These highly bullish long-term signals suggest that Wall Street is treating Insilico as it did SCI almost three decades ago.

No One Wanted Nvidia Either

There’s one important point I should make about investing:

You don’t get points for style.

Instead, markets reward you for buying great businesses at low prices.

Consider Nvidia Corp. (NVDA). In October 2022, Nvidia was a video-game chip maker with a side business in crypto mining rigs that had just lost two-thirds of its value in a crypto hangover. Analysts were slashing targets, and shares traded around $11, adjusted for splits.

It was the SCI of the computing world, and investors were leaving it for dead.

Four years later, Nvidia is now one of the most valuable companies on Earth.

Insilico is now facing a similar moment. That’s why shares have such enormous upside – and might even become Eric’s next 10X stock.

Now, there are two more stocks Eric is recommending in addition to Insilico. And these companies have potentials similar to Insilico’s: They’re using AI to revolutionize industries that most investors ignore.

Eric calls them “AI Outsiders.”

He explains the whole thesis, and why he’s watching November 30, in Life After Nvidia. His presentation premieres on Monday, November 23, at 10 a.m. Eastern.

Reserve your free seat here.

I’ll see you back here next Sunday.

Thomas Yeung, CFA
Market Analyst, InvestorPlace

Thomas Yeung is a market analyst and portfolio manager of the Omnia Portfolio, the highest-tier subscription at InvestorPlace. He is the former editor of Tom Yeung’s Profit & Protection, a free e-letter about investing to profit in good times and protecting gains during the bad.


Article printed from InvestorPlace Media, https://investorplace.com/2026/11/one-ai-stock-to-buy-life-after-nvidia/.

©2026 InvestorPlace Media, LLC